Kiwi, I am not sure why you keep saying that AMRN should sponsor a small trial focused on sub-groups. Reduce-IT was the gold standard. There is still positive data coming out for and RWE is also emerging. If any investigator wants to further investigate, they are free to do so and I am sure AMRN can give them free drug but a full sponsorship, given the preponderance of data does not make financial or any other sense. I agree with NS; the rest of EU will eventually come on board. If anything, a better HEOR dossier leveraging RWE may be more effective.
Market Data 
Markets 
AI
